The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study

PLoS Medicine

Volumn 12, Issue 8, 2015, Pages

  Gu, Dongfeng ^a,b   He, Jiang ^c,d   Coxson, Pamela G ^e   Rasmussen, Petra W ^f   Huang, Chen ^a,b   Thanataveerat, Anusorn ^f   Tzong, Keane Y ^f   Xiong, Juyang ^g   Wang, Miao ^h   Zhao, Dong ^h   Goldman, Lee ⁱ   Moran, Andrew E ^f,i  

^a FUWAI HOSPITAL   (China)

^b State Key Laboratory of Cardiovascular Disease Department of Pathology National Center for Cardiovascular Disease   (China)

^c TULANE UNIVERSITY   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINA; CHRONIC KIDNEY DISEASE; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; HYPERTENSION; MALE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SENSITIVITY ANALYSIS; SMOKING; COST BENEFIT ANALYSIS; DRUG MONITORING; ECONOMICS; MARKOV CHAIN; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHINA; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; HUMANS; HYPERTENSION; MALE; MARKOV CHAINS; MIDDLE AGED;

EID: 84940739636     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001860     Document Type: Article

References (38)

1. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, et al. (2013) Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 381: 1987–2015. doi: 10.1016/S0140-6736(13)61097-1 23746901
2. Wang J, Zhang L, Wang F, Liu L, Wang H, et al. (2014) Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens 27: 1355–1361. doi: 10.1093/ajh/hpu053 24698853
3. Yu B, Zhang X, Wang G, (2013) Full coverage for hypertension drugs in rural communities in China. Am J Manag Care 19: e22–29. 23379776
4. Zhang M, Meng Y, Yang Y, Liu Y, Dong C, et al. (2011) Major inducing factors of hypertensive complications and the interventions required to reduce their prevalence: an epidemiological study of hypertension in a rural population in China. BMC Public Health 11: 301. doi: 10.1186/1471-2458-11-301 21569365
5. Tang JL, Wang WZ, An JG, Hu YH, Cheng SH, et al. (2010) How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city. Int J Epidemiol 39: 244–254. doi: 10.1093/ije/dyp213 19491141
6. Yip WC, Hsiao WC, Chen W, Hu S, Ma J, et al. (2012) Early appraisal of China's huge and complex health-care reforms. Lancet 379: 833–842. doi: 10.1016/S0140-6736(11)61880-1 22386036
7. Tang S, Tao J, Bekedam H, (2012) Controlling cost escalation of healthcare: making universal health coverage sustainable in China. BMC Public Health 12 Suppl 1: S8. doi: 10.1186/1471-2458-12-S1-S8 22992484
8. Moran A, Gu D, Zhao D, Coxson P, Wang YC, et al. (2010) Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china. Circ Cardiovasc Qual Outcomes 3: 243–252. doi: 10.1161/CIRCOUTCOMES.109.910711 20442213
9. Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, et al. (2014) Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. Circ Cardiovasc Qual Outcomes 7: 78–85. doi: 10.1161/CIRCOUTCOMES.113.000674 24425706
10. Liu LS, Writing Group of Chinese Guidelines for the Management of Hypertension (2011) [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi 39: 579–615. 22088239
11. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159–2219. doi: 10.1093/eurheartj/eht151 23771844
12. Lozano R, Murray C.J.L., Lopez A.D., Satoh T, . (2001) Miscoding and misclassification of ischaemic heart disease mortality. Global Programme on Evidence for Health Policy Working Paper No. 12. Geneva, World Health Organization.
13. Liu J, Hong Y, D'Agostino RB, Sr.Wu Z, Wang W, et al. (2004) Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 291: 2591–2599. 15173150
14. Law MR, Morris JK, Wald NJ, (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665. doi: 10.1136/bmj.b1665 19454737
15. Law MR, Wald NJ, Morris JK, Jordan RE, (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427. 12829555
16. Turnbull F, Blood Pressure Lowering Treatment Trialists Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535. 14615107
17. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913. 12493255
18. Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, et al. (2015) Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med 372: 447–455. doi: 10.1056/NEJMsa1406751 25629742
19. (2009) The Ministry of Health of the People's Republic of China. China's Health Statistics Yearbook 2009. Beijing: the Peking Union Medical College Press
20. Huffman MD, Rao KD, Pichon-Riviere A, Zhao D, Harikrishnan S, et al. (2011) A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One 6: e20821. doi: 10.1371/journal.pone.0020821 21695127
21. (2011) CHOosing Interventions that are Cost Effective (WHO-CHOICE). World Health Organization.
22. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, et al. (2012) Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380: 2129–2143. doi: 10.1016/S0140-6736(12)61680-8 23245605
23. Hellermann JP, Goraya TY, Jacobsen SJ, Weston SA, Reeder GS, et al. (2003) Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol 157: 1101–1107. 12796046
24. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, et al. (2011) Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378: 1231–1243. doi: 10.1016/S0140-6736(11)61215-4 21872920
25. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M, (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336: 1114–1117. doi: 10.1136/bmj.39553.670231.25 18480115
26. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253–1258. 8849754
27. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, et al. (2007) Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 370: 2054–2062. 18063025
28. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, et al. (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507–520. doi: 10.1001/jama.2013.284427 24352797
29. Li Y, Ying C, Sufang G, Brant P, Bin L, et al. (2013) Evaluation, in three provinces, of the introduction and impact of China's National Essential Medicines Scheme. Bull World Health Organ 91: 184–194. doi: 10.2471/BLT.11.097998 23476091
30. Johns B, Baltussen R, Hutubessy R, (2003) Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 1: 1. 12773220
31. Bai Y, Zhao Y, Wang G, Wang H, Liu K, et al. (2013) Cost-effectiveness of a hypertension control intervention in three community health centers in China. J Prim Care Community Health 4: 195–201. doi: 10.1177/2150131912470459 23799707
32. Wang X, Li W, Li X, An N, Chen H, et al. (2013) Effects and cost-effectiveness of a guideline-oriented primary healthcare hypertension management program in Beijing, China: results from a 1-year controlled trial. Hypertens Res 36: 313–321. doi: 10.1038/hr.2012.173 23154592
33. Liang XH, Gu DF, Zhang H, Zhu K, Deng Y, et al. (2011) [The analysis of drug cost and direct medical expense in community health management of hypertensive patients]. Zhonghua Yu Fang Yi Xue Za Zhi 45: 732–736. 22169696
34. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, et al. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 346: f1049. doi: 10.1136/bmj.f1049 23529982
35. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, et al. (2014) ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation 129: 2329–2345. doi: 10.1161/CIR.0000000000000042 24677315
36. Rodgers A, Lawes CMM, Gaziano T, Vos T, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, (2006) The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight. In: Disease Control Priorities in Developing Countries. New York: Oxford University Press and the World Bank.
37. Wang H, Yip W, Zhang L, Wang L, Hsiao W, (2005) Community-based health insurance in poor rural China: the distribution of net benefits. Health Policy Plan 20: 366–374. 16143589
38. Niu S, Zhao D, Zhu J, Liu J, Liu Q, et al. (2009) The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project. Am Heart J 157: 709–715 e701. doi: 10.1016/j.ahj.2008.12.009 19332200